Access, sustainability and manufacturing competitiveness highlighted at global generic, biosimilar and value added pharmaceutical conference in Budapest

Budapest, 14th June 2018. Industry leaders from the generic, biosimilar and value added medicines industries discuss challenges and opportunities in ensuring sustainable, worldwide patient access to pharmaceuticals. Medicines for Europe and the International Generic and Biosimilar Medicines Association (IGBA) join forces to tackle challenges such as market sustainability, medicines shortages, and international regulatory cooperation. Opportunities can be pursued with strong stakeholder collaboration for a sustainable industry. These include the introduction of an EU SPC manufacturing waiver, and ensuring that generic, biosimilar and value added medicines can play their role in providing better access for better health.   

Read More





We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site